Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity

Cancer

Volumn 85, Issue 1, 1999, Pages 134-144

  Borsellino, Nicolò ^a   Bonavida, Benjamin ^b   Ciliberto, Gennaro ^c   Toniatti, Carlo ^c   Travali, Salvatore ^d   D'Alessandro, Natale ^a,e  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c IRBM   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

Author keywords

Drug resistance; Gp130; Interleukin 6; Oncostatin M; Prostate cancer; Resistance factors

Indexed keywords

CISPLATIN; ETOPOSIDE; GENISTEIN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; OLIGONUCLEOTIDE; ONCOSTATIN M; TERPENE;

ARTICLE; CELL GROWTH; CYTOTOXICITY; DNA PROBE; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL FILTRATION; GENE MUTATION; HUMAN; HUMAN CELL; ISOPRENYLATION; MULTIDRUG RESISTANCE; ONCOGENE RAS; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL CULTURE; TUMOR GROWTH;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CISPLATIN; CYCLOHEXENES; CYTOKINE RECEPTOR GP130; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENISTEIN; HUMANS; INTERLEUKIN-6; MALE; MEMBRANE GLYCOPROTEINS; MONOTERPENES; ONCOSTATIN M; PEPTIDES; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TERPENES; TUMOR CELLS, CULTURED;

EID: 0032922590     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990101)85:1<134::AID-CNCR19>3.0.CO;2-C     Document Type: Article

References (49)

1. Pinedo HM, Giaccone G. P-glycoprotein - a marker of cancer cell behavior. N Engl J Med 1995;333:1417-9.
2. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. P53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
3. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren AM. Wild-type p53 induced apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature (London) 1991;352:345-7.
4. Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapeutic compounds in myeloid leukemic cells. Blood 1992;80:1750-7.
5. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6 receptor monoclonal antibody. Cancer Res 1995;55:590-6.
6. Tsai CM, Chang KT, Perng RP, Mitsudomi T, Chen MH, Kadoyama C, et al. Correlation of intrinsic chemoresistance of non-small cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993;85:897-901.
7. Sell C, Baserga R, Rubin R. Insulin-like growth factor (IGF-1) and the IGF-1 receptor prevent etoposide-induced apoptosis. Cancer Res 1995;55:303-6.
8. Akira S, Taka T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;4:1-78.
9. Kawano M, Hirano T, Matsuda T, Taga H, Horii Y, Iwato K, et al. Autocrine generation and requirement of BSF/IL-6 for human multiple myelomas. Nature (London) 1988;332: 83-5.
10. Miki S, Iwani M, Miki Y, Yamamoto M, Tang B, Yokokawa K, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinoma. FEBS Lett 1989;250: 607-10.
11. Eustage D, Han X, Gooding R, Rowbottom A, Riches P, Heyderman E. Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinoma in vitro. Gynecol Oncol 1993;50:15-9.
12. Miles S, Rezai AR, Salazar-Gonzales JF, Meyden MV, Stevens RH, Logan DM, et al. AIDS Kaposi's sarcoma-derived cells produce and respond to interleukin-6. Proc Natl Acad Sci USA 1990;87:4068-72.
13. Yee C, Biondi A, Wang XH, Iscove NN, de Sousa I, Aarden LA, et al. A possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood 1989;4:798-804.
14. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin-6 (IL-6) is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995;55:4633-9.
15. Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN β2) receptor. Science 1988;241:825-8.
16. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990;63:1149-57.
17. Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K, et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993;260:1808-10.
18. Fukada T, Hibi M, Yamanaka Y, Takahashi-Tezuka M, Fujitani Y, Yamaguchi T, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 1996;5:449-60.
19. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992;258:593-7.
20. Liu J, Modrell B, Aruffo A, Marken JS, Taga T, Yasukawa K, et al. Interleukin-6 signal transducer gp130 mediates oncostatin M signaling. J Biol Chem 1992;267:16763-6.
21. Paonessa G, Graziani R, De Serio A, Savino R, Ciapponi L, Lahm A, et al. Two distinct and independent sites on IL-6 trigger gp130 dimer formation and signaling. EMBO J 1995; 14:1942-51.
22. De Serio A, Graziani R, Laufer R, Ciliberto G, Paonessa G. In vitro binding of ciliary neurotrophic factor to its receptor: evidence for the formation of an IL-6-type hexameric complex. J Mol Biol 1995;254:795-800.
23. Yoshida K, Taga T, Saito M, Suematsu S, Kumanogoh A, Tanaka T, et al. Targeted disruption of gp130, a common signal transducer for the interleukin-6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA 1996;93:407-11.
24. Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin MN, Todaro GJ. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci USA 1986;83:9739-43.
25. Cai J, Gill PS, Masood R, Chandrasoma P, Jung B, Law RE, et al. Oncostatin-M is an autocrine growth factor in Kaposi's sarcoma. Am J Pathol 1994;145:74-9.
26. Linsley PS, Bolton-Hanson M, Horn D, Malik N, Kallestad JC, Ochs V, et al. Identification and characterization of cellular receptors for the growth regulator, oncostatin M. J Biol Chem 1989;264:4282-9.
27. Sporeno E, Savino R, Ciapponi L, Paonessa G, Cabibbo A, Lahm A, et al. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells. Blood 1996;87:4510-9.
28. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Holz MA, Lassota P, et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992;13:795-8.
29. Aapro MS, Alberts DS, Salmon SE. Interactions of human leukocyte Interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 1983;10:161-8.
30. Thayer G, Schirmböck M, Thalhammer T, Sherwood ER, Baumgartner G, Hamilton G. Role of the MDR-1-encoded phenotype in prostate cancer cell lines. J Urol 1993;150: 1544-7.
31. Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, et al. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 1995; 55:2122-8.
32. Thompson DS, Hainsworth JD, Hande KR, Holzmer MC, Greco A. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J Clin Oncol 1993;11:1322-8.
33. Crowell PL, Ren Z, Lin S, Vedejs E, Gould MN. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 1994;47:1405-15.
34. Marshall CJ. Opportunities for pharmacological intervention in the ras pathway. Ann Oncol 1995;6(Suppl 1):63-7.
35. Sporn MB, Roberts A. Autocrine growth factors and cancer. Nature (London) 1985;313:745-7.
36. Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibition to autocrine stimulator during human melanoma progression. J Cell Biol 1993;120:1281-8.
37. Siegall CB, Schwab G, Nordan RP, Fitzgerald DJ, Pastan I. Expression of the interleukin-6 receptor and interleukin-6 in prostate carcinoma cells. Cancer Res 1990;50:7786-8.
38. Twille DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995;45:542-9.
39. Keller ET, Chang C, Ershler WB. Dihydrotestosterone suppresses interleukin-6 expression in LNCaP prostate cancer cells. Proc Am Assoc Cancer Res 1996;37:88.
40. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing p53 alleles. Cancer Res 1991;51:4716-20.
41. Diniens WN, Van der Weiden MM, Schroeder FH, Bosman FT, Trapman J. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 1994;56:630-3.
42. Sehgal PB, Wang L, Rayanade R, Pan H, Margulies L. Interleukin-6-type cytokines. Ann NY Acad Sci 1995;762:1-14.
43. Black K, Garrett IR, Mundy GR. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology 1991;128:2657-9.
44. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N, et al. Relationship between serum levels of interleukin-6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996;56:2776-80.
45. Tanner J, Tosato G. Impairment of natural killer functions by interleukin-6 increases lymphoblastoid cell tumorgenicity in athymic mice. J Clin Invest 1991;88:239-47.
46. Demartis A, Bernassola F, Savino R, Melino G, Ciliberto G. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death. Cancer Res 1996;56: 4213-8.
47. Wingo PA, Tong T, Bolden S. Cancer statistics 1995. CA Cancer J Clin 1995;45:8-30.
48. Klein B, Brailly H. Cytokine-binding proteins: stimulating antagonists. Immunol Today 1995;16:216-20.
49. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274:1379-83.